Bioventus Inc. (BVS) Stock Price & Analysis
Bioventus Inc. (BVS) rose 2.79% to USD 9.2 as of June 10, 2026 at 02:00 UTC, according to Nexqual real-time market data.
BVS last closed at USD 8.95; the session ranged USD 8.98–9.3 on volume of 478,852 shares. Market capitalization is $623.28M, with a 52-week range of USD 5.81–11.25 (NMS). Source: Nexqual, June 10, 2026 at 02:00 UTC.
Key Statistics (as of June 10, 2026 at 02:00 UTC)
| Price | USD 9.2 |
|---|---|
| Change | ▲ 2.79% (up) |
| Previous Close | USD 8.95 |
| Open | USD 8.98 |
| Day Range | USD 8.98 – 9.3 |
| 52-Week Range | USD 5.81 – 11.25 |
| Volume | 478,852 shares |
| Market Cap | $623.28M |
| Exchange | NMS |
Technical Analysis (BVS)
Nexqual's technical model rates BVS "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:00 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 48.59 (neutral) |
| vs SMA50 | Below (USD 9.66) |
| MACD | -0.32 (negative) |
Analyst Ratings (BVS)
Wall Street analysts rate BVS "None" based on 5 analysts, with a mean price target of USD 14.8 (range USD 14–16), per Nexqual as of June 10, 2026 at 02:00 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 14.8 |
| High Target | USD 16 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (BVS)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.22 |
| Revenue Estimate | $155.45M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.15 vs est 0.07 ▲ beat |
| 2025-12-31 | USD 0.24 vs est 0.22 ▲ beat |
| 2025-09-30 | USD 0.15 vs est 0.12 ▲ beat |
| 2025-06-30 | USD 0.21 vs est 0.2 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Financials & Fundamentals (BVS)
| Total Revenue | $576.30M |
|---|---|
| Revenue Growth (YoY) | +6.60% |
| Gross Margin | +68.69% |
| Operating Margin | +6.73% |
| Profit Margin | +4.94% |
| ROE | +16.46% |
| Debt / Equity | 123.12 |
| Current Ratio | 1.69 |
| Total Cash | $35.85M |
| Total Debt | $288.42M |
| Free Cash Flow | $63.31M |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Financial Health Score (BVS)
Nexqual rates Bioventus Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:00 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 69%, operating 7% |
| Balance Sheet | Mixed — $36M cash vs $288M debt |
| Cash Flow | Solid — FCF $63M, 11% margin |
| Efficiency | Solid — ROE 16%, ROA 5.6% |
Ownership (BVS)
| Insider Ownership | +11.75% |
|---|---|
| Institutional Ownership | +78.28% |
| Shares Outstanding | 67.75M |
| Float | 33.31M |
| Short % of Float | +3.97% |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Leadership (BVS)
Bioventus Inc. is led by Robert E. Claypoole (age 53), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:00 UTC.
| President, CEO & Director | Robert E. Claypoole (age 53) |
|---|---|
| Senior VP & CFO | Mark L. Singleton (age 56) |
| Senior Vice President of Operations | Mike Crowe B.S. |
| Vice President of Investor Relations & Treasurer | David Crawford |
Major Backers & Investors (BVS)
Notable institutional backers of Bioventus Inc. include Essex Woodlands Management Inc., Juniper Investment Company, LLC, Nantahala Capital Management, LLC, according to Nexqual as of June 10, 2026 at 02:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Essex Woodlands Management Inc. | 19.22% |
| Juniper Investment Company, LLC | 10.24% |
| Nantahala Capital Management, LLC | 9.04% |
| Royce & Associates LP | 2.28% |
| Fidelity | 1.26% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.81% |
| Vanguard Group | 6.45% |
| Geode Capital | 1.72% |
| State Street | 1.46% |
| Dimensional Fund Advisors | 1.29% |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
From Bioventus Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
- It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.
- The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products.
- Its products also include Exogen, an ultrasound bone stimulation system.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANNX | Annexon, Inc. | USD 5.2 | ▼ 1.7% |
| TMCI | Treace Medical Concepts, Inc. | USD 3.73 | ▲ 6.27% |
| AVAH | Aveanna Healthcare Holdings Inc | USD 6.87 | ▲ 2.84% |
| AFIB | Acutus Medical Inc. | USD 0 | ▲ 0% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:00 UTC. This page is informational and not investment advice.